Last reviewed · How we verify
Improving Obesity Self-Care Among Mentally Ill Veterans
NA trial testing MH MOVE in Anxiety in 44 participants. Completed in 31 December 2016.
| Lead sponsor | VA Office of Research and Development |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 1 January 2011 |
| Primary completion | 31 December 2016 |
| Estimated completion | 31 December 2016 |
| Sites | 1 location across United States |
VA Office of Research and Development — full company profile →
18 and older, any sex, with Anxiety or Depression. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of MOVE! sessions attended minimum-maximum total score range (2-12) Higher value represents more sessions attended The score was obtained from a single item
| Group | Value | 95% CI |
|---|---|---|
| MH MOVE | 5.9 | ± 1.8 |
| Enhanced Usual Care | 5.8 | ± 1.8 |
changes in vigor and time spent on physical activity practice will be measured by the MOVE! 11 assessment at post treatment (16 weeks) minimum-maximum total score range (0-48) Higher value represents more days spent performing vigorous activity
| Group | Value | 95% CI |
|---|---|---|
| MH MOVE | 21.5 | ± 11.5 |
| Enhanced Usual Care | 26.9 | ± 18 |
Initial assessment of vigor and time spent on physical activity minimum-maximum total score range (0-32) Higher value represents more days spent performing vigorous physical activity The score was obtained from a single item
| Group | Value | 95% CI |
|---|---|---|
| MH MOVE | 27.7 | ± 22.1 |
| Enhanced Usual Care | 28.1 | ± 15.3 |
Self-efficacy for practicing healthy dietary habits during difficult times will be assessed at baseline and post treatment (16 weeks) minimum-maximum total score range (20-100) Higher value represents greater sense of self-efficacy for healthy eating during difficult times The score was obtained from 3 subscales
| Group | Value | 95% CI |
|---|---|---|
| MH MOVE | 32.3 | ± 19.2 |
| Enhanced Usual Care | 29.8 | ± 6.0 |
Self-efficacy for practicing healthy dietary habits during difficult times will be assessed at baseline and post treatment (16 weeks) minimum-maximum total score range (20-100) Higher value represents greater sense of self-efficacy for healthy eating during difficult times The score was obtained from 3 subscales
| Group | Value | 95% CI |
|---|---|---|
| MH MOVE | 29.9 | ± 10.4 |
| Enhanced Usual Care | 23.2 | ± 7.4 |
Changes in depression symptom severity will be measured at baseline and post treatment (16 weeks) minimum-maximum total score range (0-24) Higher value represents greater depressive symptom severity An overall score was obtained from the 8-item measure.
| Group | Value | 95% CI |
|---|---|---|
| MH MOVE | 6.3 | ± 7.1 |
| Enhanced Usual Care | 13.4 | ± 6.2 |
Anxiety symptom severity will be measured by the GAD-7 at baseline and post treatment (16 weeks) minimum-maximum total score range (0-21) Higher value represents greater anxiety symptom severity An overall score was obtained from the 7-item measure.
| Group | Value | 95% CI |
|---|---|---|
| MH MOVE | 5.5 | ± 6.5 |
| Enhanced Usual Care | 10.5 | ± 6.7 |
PTSD symptom severity will be measured by the PCL-M at baseline and post treatment (16 weeks) minimum-maximum total score range (17-85) Higher value represents greater PTSD symptom severity An overall score was obtained from 4 subscales.
| Group | Value | 95% CI |
|---|---|---|
| MH MOVE | 32.1 | ± 20.8 |
| Enhanced Usual Care | 53 | ± 18 |
Changes in depression symptom severity will be measured at baseline and post treatment (16 weeks) minimum-maximum total score range (0-24) Higher value represents greater depressive symptom severity An overall score was obtained from the 8-item measure.
| Group | Value | 95% CI |
|---|---|---|
| MH MOVE | 19 | ± 21.7 |
| Enhanced Usual Care | 15 | ± 19.3 |
Anxiety symptom severity will be measured by the GAD-7 at baseline and post treatment (16 weeks) minimum-maximum total score range (0-21) Higher value represents greater anxiety symptom severity An overall score was obtained from the 7-item measure.
| Group | Value | 95% CI |
|---|---|---|
| MH MOVE | 8 | ± 13.8 |
| Enhanced Usual Care | 16 | ± 19.7 |
PTSD symptom severity will be measured by the PCL-M at baseline and post treatment (16 weeks) minimum-maximum total score range (17-85) Higher value represents greater PTSD symptom severity An overall score was obtained from 4 subscales.
| Group | Value | 95% CI |
|---|---|---|
| MH MOVE | 39 | ± 26.5 |
| Enhanced Usual Care | 25 | ± 73.5 |
The purpose of this study is to find out which of two programs, MH MOVE! or the enhanced usual care MOVE! program is most effective in improving participation in and completion of MOVE! among Veterans with depression, anxiety, and PTSD. One of the treatments, MH MOVE! provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions. The enhanced usual care MOVE! provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02642536.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing